This series covers in autobiographical accounts the first fifty years in the history of neuropsychopharmacology. The autobiographies in Volume I, (The Rise of Psychopharmacology and the Story of CINP) are from psychopharmacologists who began their professional careers in the 1950s and 1960s; in Volume II (The Triumph of Psychopharmacology and the Story of CINP), from those who started in the 1970s; in Volume III (From Psychopharmacology to Neuropsychopharmacology in the 1980s and the Story of CINP), who started in the 1980s; and in Volume IV (Reflections on Twentieth-Century Psychopharmacology), who started in the 1990s. At the core of each volume are personal accounts in which the contributions of the scientists, are at the center of the reflections, but also include several sections in which the reflections are focused on the mainstream of events, particular areas of research, individuals and organizations. The series was the extension of an effort by CINP's History Committee, during the chairmanship of Tom Ban, to document both the history of the College and the enire field. It was co-edited by Ban, David Healy and Edward Shorter. Its publication was supported by the College primarily from non-restricted publication grants received from Pierre Fabre, Janssen Pharmaceutica and Research Foundation,Inc., and Janssen Phamaceutica International in Collaboration with Organon International.

In The Rise and Fall of the Age of Psychopharmacology, esteemed historian Edward Shorter proposes that the recent history of psychiatry is that of a failed scientific discipline of medicine. Medicine generally is about the story of progress, but psychiatry's story is that of failure in diagnosis, in therapeutics, and in the ability to deliver science-based care to suffering individuals.

Neuropsychopharmacology reviews the principles of pharmacology with a focus on the central nervous system and autonomic nervous system. Beyond autonomic and central nervous system pharmacology, this volume uniquely discusses psychiatric disorders and the pharmacological interventions that are available for conditions including depression, schizophrenia and anxiety disorders. With a focus on these specific body systems, readers will see end-of-chapter questions that offer real-world case studies, as well as multiple-choice questions for further learning. Beneficial features and content also include two extensive examination tests, which each contain 100 questions for better learning or to be used in teaching, and a glossary. Helpful appendices cover high-alert medications and toxicology effects on the nervous system. Each chapter will contain classifications of medications, pharmacokinetics, mechanism of action, clinical indications and toxicities. - Describes pharmacology principles pertaining to the central and autonomic nervous system - Identifies pharmacological interventions for psychiatric disorders including current evidence-based interventions for depression, schizophrenia and anxiety disorders - Features chapter outlines, end-of-chapter questions, real-world case studies and examinations for deeper learning or teaching

This provocative history of bipolar disorder illuminates how perceptions of illness, if not the illnesses themselves, are mutable over time. Beginning with the origins of the concept of mania—and the term maniac—in ancient Greek and Roman civilizations, renowned psychiatrist David Healy examines how concepts of mental afflictions evolved as scientific breakthroughs established connections between brain function and mental illness. Healy recounts the changing definitions of mania through the centuries, explores the effects of new terminology and growing public awareness of the disease on culture and society, and examines the rise of psychotropic treatments and pharmacological marketing over the past four decades. Along the way, Healy clears much of the confusion surrounding bipolar disorder even as he raises crucial questions about how, why, and by whom the disease is diagnosed. Drawing heavily on primary sources and supplemented with interviews and insight gained over Healy's long career, this lucid and engaging overview of mania sheds new light on one of humankind's most vexing ailments.

Clinical Psychopharmacology offers a comprehensive guide to clinical practice that explores two major aspects of the field: the clinical research that exists to guide clinical practice of psychopharmacology, and the application of that knowledge with attention to the individualized aspects of clinical practice. The text consists of 50 chapters, organized into 6 sections, focusing on disease-modifying effects, non-DSM diagnostic concepts, and essential facts about the most common drugs. This innovative book advocates a scientific and humanistic approach to practice and examines not only the benefits, but also the harms of drugs. Providing a solid foundation of knowledge and a great deal of practical information, this book is a valuable resource for practicing psychiatrists, psychiatric nurse practitioners, medical students and trainees in psychiatry, as well as pharmacists.

Recent scientific developments, in particular advances in pharmacogenetics and molecular genetics, have given rise to numerous predictive procedures for detecting predispositions to diseases in patients. This knowledge, however, does not necessarily promise benign results for either patients or health care professionals. The aim of this volume is to analyse issues related to prediction and prognosis as a burgeoning field of medicine, which is revolutionizing the way we understand and approach diagnosis and treatment. Combining epistemic and ethical reflection with medical expertise on contemporary practice and research, an interdisciplinary group of international experts critically examine anticipatory medicine from various perspectives, including history of medicine, bioethics, theories of science, and health economics. The highly complex issues involved in medical prediction call for a far-reaching debate on the value and scope of foreknowledge. For example, which responsibilities and burdens arise when still healthy people learn of their predisposition to diseases? How should health care insurance reflect risky life styles? Is the increasing medicalization of life connected with prevention ethically sustainable and financially possible in the developing world? These and other related issues are the subject of this timely and important book, which not only serves as an introduction to the area, but also proposes many feasible solutions to the problems outlined.

Do antidepressants work, or are they glorified dummy pills? How can we tell? In Ordinarily Well, the celebrated psychiatrist and author Peter D. Kramer examines the growing controversy about the popular medications. A practicing doctor who trained as a psychotherapist and worked with pioneers in psychopharmacology, Kramer combines moving accounts of his patients’ dilemmas with an eye-opening history of drug research to cast antidepressants in a new light. Kramer homes in on the moment of clinical decision making: Prescribe or not? What evidence should doctors bring to bear? Using the wide range of reference that readers have come to expect in his books, he traces and critiques the growth of skepticism toward antidepressants. He examines industry-sponsored research, highlighting its shortcomings. He unpacks the “inside baseball” of psychiatry—statistics—and shows how findings can be skewed toward desired conclusions. Kramer never loses sight of patients. He writes with empathy about his clinical encounters over decades as he weighed treatments, analyzed trial results, and observed medications’ influence on his patients’ symptoms, behavior, careers, families, and quality of life. He updates his prior writing about the nature of depression as a destructive illness and the effect of antidepressants on traits like low self-worth. Crucially, he shows how antidepressants act in practice: less often as miracle cures than as useful, and welcome, tools for helping troubled people achieve an underrated goal—becoming ordinarily well.